QuidelOrtho : Appoints Juliet Cunningham as Vice President of Investor Relations
September 11, 2023 at 12:41 pm EDT
SAN DIEGO, CA - September 11, 2023 - QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointment of Juliet Cunningham as its Vice President of Investor Relations, effective September 5, 2023.
"I am pleased to welcome Juliet as our new Vice President of Investor Relations," said Joseph Busky, Chief Financial Officer. "Juliet is a tenured investor relations professional with a demonstrated track record in the medical technology sector. Her extensive financial and investor relations experience and deep industry knowledge will be a strong addition to our team as we continue to make headway in our integration and growth trajectory. We look forward to Juliet's contribution to our investor relations program."
Ms. Cunningham added, "I am extremely excited to join QuidelOrtho at such a great inflection point in the Company's growth story. QuidelOrtho is at the nexus of healthcare and technology, with leading capabilities giving medical professionals critical answers at critical times. With the Savanna approvals underway, and the focus on operational enhancement through its growth transformation, QuidelOrtho is poised for its next phase of opportunity. I look forward to working alongside the team as we continue the mission of meeting the needs of healthcare workers around the world and enhancing our investor relations capabilities."
Ms. Cunningham brings over 30 years of financial and investor relations expertise to QuidelOrtho, having most recently served as Vice President of Investor Relations at NuVasive prior to being acquired by Globus Medical. Before her role at NuVasive, Ms. Cunningham served as the Vice President of Investor Relations at Nevro Corporation. Prior to Nevro, Ms. Cunningham was Vice President of Investor Relations at Alere Inc., which was purchased by Abbott and is now known as Abbott Rapid Diagnostics. She served as Senior Vice President of Investor Relations & Corporate Communications at Qualcomm during a decade of the company's highest growth. Ms. Cunningham holds a bachelor's degree in business administration and completed graduate certifications at the University of Michigan and Stanford University in Theory & Practice of Investor Relations, and Executive Leadership, respectively.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.
Ranked among the world's largest in vitro diagnostics (IVD) providers with more than 120 years of collective experience, we combine industry-leading expertise in immunoassay and molecular testing with a global footprint in clinical labs and transfusion medicine.
Our company's comprehensive product portfolio delivers accuracy, speed, automation and access, providing critical information when and where it is needed most. Inspired by a spirit of service, QuidelOrtho is committed to enhancing the well-being of people worldwide and happy in the knowledge we are making a difference. For more information, please visit www.quidelortho.com.
Source: QuidelOrtho Corporation
Quidelortho Corporation published this content on 11 September 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 September 2023 16:40:04 UTC.
QuidelOrtho Corporation is a vitro diagnostics company. The Company is engaged in the development and manufacturing of advanced technologies in diagnostic testing. Its capabilities include immunoassay and molecular testing, clinical chemistry and transfusion medicine. The Company's business units include Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine. Its Labs business unit includes Virology, Specialty Products, Specialty Products, Immunodiagnostics, VITROS Platform, XT Platform, VITROS XT Platform, and VITROS Automation Solutions. Its Molecular Diagnostics business includes Lyra, Solana, and Savanna. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, D, ELVIRA, ELVIS, FastPoint, FreshCells, InflammaDry, Lyra, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Vision, Quidel, QuickVue, QuickVue+, QVue, ReadyCells, Savanna, Sofia, Solana, Thyretain, Triage, Virena, and Vitros.